

# NRG Scientific Session NRG Oncology Research Review

**Date:** Friday, January 22, 2016  
**Start and End Time:** 8:00 am – 10:00 am  
**Co-Chairs** Carmen Allegra, MD; Deborah Bruner, PhD; Fred Stehman, MD; Maria Werner Wasik, MD  
**Moderator** Fred Stehman, MD

## Learning Objectives:

**Following this activity, participants will be better able to:**

1. Discuss the National Institutes of Health (NIH) requirement that copies of all publications funded by National Cancer Institute (NCI) grants must be available for public viewing and review the process for submitting and confirming the document.
2. Discuss the results of recently reported trials for centrally located non-small cell lung cancer (NSCLC); low-risk prostate cancer; ovarian, primary peritoneal or fallopian tube cancer; p16-positive oropharyngeal squamous cell cancer; and breast cancer.
3. Describe changes in cognitive function during chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer.
4. Describe the role of stereotactic body radiotherapy (SBRT) for centrally located non-small cell lung cancer (NSCLC).
5. Describe the role of 2 different radiation therapy fractionation schedules in patients with low-risk prostate cancer.
6. Identify the prognostic groups for p16-positive oropharyngeal squamous cell cancer (p16-OPSCC) treated with chemoradiotherapy (CRT).
7. Discuss the results of a prospective validation of a 21-gene expression assay in breast cancer.

## WORKSHOP AGENDA

8:00 – 8:15 am	Review of the NIH Manuscript Submission Requirements	Deborah Bruner, PhD Fred Stehman, MD
8:15 – 8:30 am	NCI's Study Champion Program and Implementation	Andrea Denicoff, MS, RN, ANP
8:30 – 8:40 am	Cognitive function during chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: an NRG Oncology/Gynecologic Oncology Group study.	William Robinson, MD
8:40 – 8:48 am	Discussant & Questions	Vinai Gondi, MD
8:48 – 8:58 am	Primary study endpoint analysis for NRG Oncology/RTOG 0813 trial of stereotactic body radiotherapy (SBRT) for centrally located non-small cell lung cancer (NSCLC).	Andrea Bezjak, MD
8:58 – 9:06 am	Discussant & Questions	Cliff Robinson, MD
9:06 – 9:16 am	NRG Oncology/RTOG 0415: A randomized phase III non-inferiority study comparing 2 fractionation schedules in patients with low-risk prostate cancer.	Howard Sandler, MD
9:16 – 9:24 am	Discussant-Questions	Mark Hurwitz, MD
9:24 – 9:34 am	Prognostic groups for p16-positive oropharyngeal squamous cell cancer (p16-OPSCC) treated with chemoradiotherapy (CRT) in NRG Oncology/RTOG 0129 and 0522.	Carole Fakhry, MD
9:34 – 9:42 am	Discussant & Questions	Adam Dicker, MD, PhD
9:42 – 10:00 am	Prospective validation of a 21-gene expression assay in breast cancer.	Charles Geyer, MD
	Discussant & Questions	Massimo Cristofanilli, MD